Our findings provide novel insights into how tumor cells evade immune clearance through lipid metabolic rewiring and suggest that TACC3 is a promising target for enhancing immunotherapy efficacy in HCC. The gene discussed is TACC3; the disease is hepatocellular carcinoma.